Dr Jagdish Kumar Jaiswal

BPharm, MPharm, PhD

Research Fellow

In: Auckland Cancer Society Research Centre » Medical Science » Faculty of Medical and Health Sciences

Biography

B. Pharm - Institute of Technology, Banaras Hindu University (India)
M. Pharm (Pharmaceutics) - Jadavpur University (India)
PhD (Pharmacology) - All India Institute of Medical Sciences (India)
Visiting DAAD Fellow in the laboratories of Prof. Jorg Kreuter at Frankfurt Biocentre, Johann Wolfgang Goethe University, Germany
Research Associate (Drug Discovery- Pharmacology)- Torrent Research Centre, India
Post doctoral research fellow - Auckland Cancer Society Research Centre (2005-2007)

Research interests

Current Projects

Small molecules perforin inhibitor (Wellcome Trust, UK)

Past projects

Clinical Phase I candidate PR-610. Pre-clinical pharmacokinetic studies (PIs- Drs Adam Patterson and Jeff Smaiil)
Clinical Phase II/III candidate PR-104. Formulation stability and rat toxicity study (Principal Investigator - Prof. Bill Wilson)
Clinical development candidate CEN-209 (SN30000). preclinical ADME studies (Principal Investigator - Prof. Bill Wilson)
NitroCBI analogs. Preclinical ADME studies (Principal Investigators Drs. Frederik Pruijn and Moana Tercel)

Research | Current

ADME/Tox of anti cancer drugs in pre-clinical development
LC-MS/MS method development

Postgraduate supervision

Small animal pharmacokinetic studies

Bioanalysis

Responsibilities

Pre clinical DMPK studies (small animals)

Bio-analysis (LC-MS/MS, LC-MS, Ion trap, HPLC)

Areas of expertise

Preclinical drug development of small molecules

Measurement of drug, metabolites in biological matrix (serum, plasma, saliva etc) by LC-MS/MS, HPLC.

Selected publications and creative works (Research Outputs)

Spicer, J. A., Miller, C. K., O'Connor PD, Jose, J., Giddens, A. C., Jaiswal, J. K., ... Akhlaghi, H. (2019). Inhibition of the Cytolytic Protein Perforin Prevents Rejection of Transplanted Bone Marrow Stem Cells in Vivo. Journal of medicinal chemistry10.1021/acs.jmedchem.9b00881
Other University of Auckland co-authors: Bill Denny, Julie Spicer, Christian Miller, Jiney Jose, Stephen Jamieson, Matthew Bull
Mao, X., McManaway, S., Jaiswal, J. K., Hong, C. R., Wilson, W. R., & Hicks, K. O. (2019). Schedule-dependent potentiation of chemotherapy drugs by the hypoxia-activated prodrug SN30000. Cancer biology & therapy, 20 (9), 1258-1269. 10.1080/15384047.2019.1617570
Other University of Auckland co-authors: Kevin Hicks
Merry, T. L., Brooks, A. E. S., Masson, S. W., Adams, S. E., Jaiswal, J. K., Jamieson, S. M. F., & Shepherd, P. R. (2019). The CSF1 receptor inhibitor pexidartinib (PLX3397) reduces tissue macrophage levels without affecting glucose homeostasis in mice. International Journal of Obesity10.1038/s41366-019-0355-7
Other University of Auckland co-authors: Anna Brooks, Troy Merry, Stephen Jamieson, Stewart Masson
Mao, X., McManaway, S., Jaiswal, J. K., Patel, P. B., Wilson, W. R., Hicks, K. O., & Bogle, G. (2018). An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids. PLoS computational biology, 14 (10)10.1371/journal.pcbi.1006469
URL: http://hdl.handle.net/2292/47071
Other University of Auckland co-authors: Gib Bogle, Kevin Hicks, William Wilson
Hong, C. R., Dickson, B. D., Jaiswal, J. K., Pruijn, F. B., Hunter, F. W., Hay, M. P., ... Wilson, W. R. (2018). Cellular pharmacology of evofosfamide (TH-302): A critical re-evaluation of its bystander effects. Biochemical pharmacology, 156, 265-280. 10.1016/j.bcp.2018.08.027
URL: http://hdl.handle.net/2292/44984
Other University of Auckland co-authors: Benjamin Dickson, Michael Hay, Frederik Pruijn, Francis Hunter, Kevin Hicks, William Wilson, Cho Rong Hong
Jose, J., Spicer, J. A., Miller, C. K., O'Connor PD, Marshal, A., Jaiswal, J., ... Law, R. H. P. (15/9/2017). Thiazolecarboxamides as inhibitors of perforin function for potential immunosuppressive therapy. Poster presented at Drug Discovery India 2017, Bengaluru, India.
Other University of Auckland co-authors: Julie Spicer, Jiney Jose, Christian Miller, Stephen Jamieson, Bill Denny
Spicer, J. A., Miller, C. K., O'Connor PD, Jose, J., Huttunen, K. M., Jaiswal, J. K., ... Trapani, J. A. (2017). Substituted arylsulphonamides as inhibitors of perforin-mediated lysis. European Journal of Medicinal Chemistry, 137, 139-155. 10.1016/j.ejmech.2017.05.048
URL: http://hdl.handle.net/2292/44150
Other University of Auckland co-authors: Christian Miller, Julie Spicer, Jiney Jose, Bill Denny
Gu, Y., Chang, T. T.-A., Wang, J., Jaiswal, J. K., Edwards, D., Downes, N. J., ... Hickey, A. J. (2017). Reductive metabolism influences the toxicity and pharmacokinetics of the hypoxia-targeted benzotriazine di-oxide anticancer agent SN30000 in mice. Frontiers in Pharmacology, 8, 1-16. 10.3389/fphar.2017.00531
URL: http://hdl.handle.net/2292/43982
Other University of Auckland co-authors: Tony Hickey, Yongchuan Gu, Frederik Pruijn, Michael Hay, William Wilson, Kevin Hicks, Courtney Lynch